Tempest Therapeutics to Present at the Solebury Trout/Credit Suisse/Cooley Private Company Showcase
March 08, 2021 16:05 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
March 03, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
January 08, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Sam Whiting, M.D., Ph.D., Joins Tempest as Executive Vice President and Chief Medical Officer
October 21, 2020 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at Two Investor Conferences in August
July 31, 2020 08:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics Announces First Patient Dosed With the Combination of TPST-1120 Plus Nivolumab in a Phase 1 Study in Patients With Advanced Solid Tumors
June 22, 2020 08:00 ET
|
Tempest Therapeutics
Combination regimen will treat patients with cholangiocarcinoma, liver and kidney cancersFirst step in broader combination strategy given TPST-1120’s novel mechanism of action SOUTH SAN FRANCISCO,...
Tempest Therapeutics Announces First Patient Dosed in TPST-1495 Clinical Study: Dual EP2/4 Antagonist Targeting Solid Tumors
May 07, 2020 08:30 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 24, 2020 16:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing therapeutics that combine both precision and immune-mediated...
Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors
January 30, 2020 08:00 ET
|
Tempest Therapeutics
TPST-1495 is a selective dual antagonist of both EP2 and EP4 prostaglandin receptorsLyfe Capital and Rock Springs Capital Management join investor syndicate SOUTH SAN FRANCISCO, Calif., Jan. 30,...